Institutional members access full text with Ovid®

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIVhepatitis C virus-coinfected patients with prior nonresponse or relapse

Labarga, Pabloa; Barreiro, Pabloa; Mira, José Ab; Vispo, Eugeniaa; Rallón, Normaa; Neukam, Karinb; Camacho, Angelac; Caruz, Antoniod; Rodriguez-Novoa, Soniaa; Pinilla, Javiere; Rivero, Antonioc; Benito, José Ma; Pineda, Juan Ab; Soriano, Vincenta

doi: 10.1097/QAD.0b013e3283471d83
Research Letters

IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7–90.9)], prior relapse [9.6 (1.5–62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3–18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9–337)].

aHospital Carlos III, Madrid, Spain

bHospital Valme, Seville, Spain

cHospital Reina Sofía, Córdoba, Spain

dUniversidad de Jaén, Jaén, Spain

eHospital San Pedro, Logroño, Spain.

Received 16 February, 2011

Revised 10 March, 2011

Accepted 24 March, 2011

Correspondence to Dr Pablo Barreiro, Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. Tel: +34 91 4532500; fax: +34 91 7336614; e-mail: pm.barreiro@gmail.com

© 2011 Lippincott Williams & Wilkins, Inc.